Androgenetic alopecia
Conditions
Interventions
Group 1: 45 participants will use 1 pill of minoxidil 2.5mg per day for 24 weeks. Clinical and trichoscopic photos will be taken before the pill and at the end of 24 weeks. Group 2: 45 participants wi
51334
9103
Sponsors
Faculdade de Medicina de Botucatu
Hospital das Clínicas de Botucatu
Eligibility
Sex/Gender
Male
Age
25 Years to 55 Years
Inclusion criteria
Inclusion criteria: male; aged between 25 and 55 years; diagnosis of androgenetic alopecia; classified on the Norwood Hamilton scale as 3V, 4V or 5V; agreeing to participate in the research
Exclusion criteria
Exclusion criteria: previous treatment for hair loss in the last 4 months; hypertensive patients; patients with heart disease; nephropathy; hepatopathy; patients with pheochromocytoma; patients with other causes of hair loss or scalp dermatoses
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the variation in the density of terminal hairs of the target area before the beginning of the treatment and after 24 weeks verified by the method of analysis of the trichoscopic photos. We will observe numbers of terminal wires, considering those with a thickness greater than 0.04 mm. The expectation is for an increase of 35 terminal hairs/cm2 in the group that will receive 5 mg/day against 12 terminal hairs/cm2 in the group that will receive 2.5 mg/day. | — |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate density variation by counting total hairs in the target area and using a 7-point comparison scale, using the standardized clinical photography assessment method by 3 dermatologists blinded to the treatment and self-assessment of patients. Higher density is expected in the group receiving 5mg/day of oral minoxidil. | — |
Countries
Brazil
Contacts
Public ContactLarissa Fonseca
Faculdade de Medicina de Botucatu
Outcome results
None listed